By a News Reporter-Staff News Editor at Pharma Business Week -- Immune Design, a biotechnology company focused on the development of novel immune-based therapies for cancer and other chronic conditions, announced the appointment of Stephen R. Brady as its Chief Business Officer (see also Immune Design).
Mr. Brady brings extensive experience to lead Immune Design's business functions, including strategic planning and corporate development activities. His appointment in this new position is a reflection of the Company's maturing immune-based therapeutic programs and productive platform technology.
"Steve is an experienced and accomplished executive with a successful track record of executing successful business development and corporate strategies," said Carlos Paya, M.D., Ph.D., President and Chief Executive Officer at Immune Design. "He is a key addition to our expanded management team and will play an important role in advancing and expanding our strategic activities."
"Immune Design's combination of both novel antigen-specific and innate immunity approaches is an exciting potential advancement in the area of cancer immunotherapy," said Mr. Brady. "I look forward to working with the team to move existing programs forward and further expand the reach of the company's platform technology in oncology, infectious disease and allergies."
Most recently, Mr. Brady served as Chief Business Officer for 3-V Biosciences, Inc., where he led business and operations activities, including finance, legal, corporate communications and strategic portfolio planning. Previously, he served as Vice President of Corporate Development for Proteolix, Inc., where he was primarily responsible for corporate development and legal affairs, including the sale of the Company to Onyx Pharmaceuticals for $851M in 2009. Prior to his tenure with Proteolix, Mr. Brady served as Senior Corporate Counsel at Lexicon Pharmaceuticals, Inc., where he served primarily in business development and legal capacities. Mr. Brady was also a Vice President with Lazard Venture Advisors, a division of Lazard Freres & Co, LLC., and an associate in the New York and San Francisco offices of Morrison & Foerster LLP. Mr. Brady received a B.A. in English from the University of Oregon and a LL.M. from New York University School of Law.
Keywords for this news article include: Technology, Immune Design, Immunotherapy, Immunomodulation.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC